Hepatitis C Virus and Antiviral Drug Resistance
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Since its discovery in 1989, hepatitis C virus (HCV) has been intensively investigated to understand its biology and develop effective antiviral therapies. The efforts of the previous 25 years have resulted in a better understanding of the virus, and this was facilitated by the development of in vitro cell culture systems for HCV replication. Antiviral treatments and sustained virological responses have also improved from the early interferon monotherapy to the current all-oral regimens using direct-acting antivirals. However, antiviral resistance has become a critical issue in the treatment of chronic hepatitis C, similar to other chronic viral infections, and retreatment options following treatment failure have become important questions. Despite the clinical challenges in the management of chronic hepatitis C, substantial progress has been made in understanding HCV, which may facilitate the investigation of other closely related flaviviruses and lead to the development of antiviral agents against these human pathogens.
Abstract
Since its discovery in 1989, hepatitis C virus (HCV) has been intensively investigated to understand its biology and develop effective antiviral therapies. The efforts of the previous 25 years have resulted in a better understanding of the virus, and this was facilitated by the development of in vitro cell culture systems for HCV replication. Antiviral treatments and sustained virological responses have also improved from the early interferon monotherapy to the current all-oral regimens using direct-acting antivirals. However, antiviral resistance has become a critical issue in the treatment of chronic hepatitis C, similar to other chronic viral infections, and retreatment options following treatment failure have become important questions. Despite the clinical challenges in the management of chronic hepatitis C, substantial progress has been made in understanding HCV, which may facilitate the investigation of other closely related flaviviruses and lead to the development of antiviral agents against these human pathogens.
참고문헌 (41)
- Alter HJ, "Clinical and serological analysis of transfusionassociated hepatitis", Lancet, 2, pp.838~841 (1975)
- Feinstone SM, "Transfusion-associated hepatitis not due to viral hepatitis type A or B", N Engl J Med, 292, pp.767~770 (1975)
- Choo QL, "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome", Science, 244, pp.359~362 (1989)
- Lohmann V, "Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line", Science, 285, pp.110~113 (1999)
- Wakita T, "Production of infectious hepatitis C virus in tissue culture from a cloned viral genome", Nat Med, 11, pp.791~796 (2005)
- Lemon SM, "Fields virology. Volume 1", pp.1253~1304 (2007), Lippincott Williams and Wilkins
- Ding Q, "The impact of hepatitis C virus entry on viral tropism", Cell Host Microbe, 16, pp.562~568 (2014)
- Paul D, "Hepatitis C virus RNA replication and assembly: living on the fat of the land", Cell Host Microbe, 16, pp.569~579 (2014)
- Miyanari Y, "The lipid droplet is an important organelle for hepatitis C virus production", Nat Cell Biol, 9, pp.1089~1097 (2007)
- Huang H, "Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins", Proc Natl Acad Sci U S A, 104, pp.5848~5853 (2007)
- Gastaminza P, "Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion", J Virol, 82, pp.2120~2129 (2008)
- Yi M, "Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells", J Virol, 78, pp.7904~7915 (2004)
- Blight KJ, "Efficient initiation of HCV RNA replication in cell culture", Science, 290, pp.1972~1974 (2000)
- Saeed M, "Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells", Antimicrob Agents Chemother, 56, pp.5365~5373 (2012)
- Saeed M, "Replication of hepatitis C virus genotype 3a in cultured cells", Gastroenterology, 144(e7), pp.56~58 (2013)
- Peng B, "Development of robust hepatitis C virus genotype 4 subgenomic replicons", Gastroenterology, 144, pp.59~61 (2013)
- Wose Kinge CN, "Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents", Antimicrob Agents Chemother, 58, pp.5386~5394 (2014)
- Yu M, "Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture", Antimicrob Agents Chemother, 58, pp.2638~2646 (2014)
- Bartosch B, "Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes", J Exp Med, 197, pp.633~642 (2003)
- Yi M, "Production of infectious genotype 1a hepatitis C virus (Hutchinson strain)in cultured human hepatoma cells", Proc Natl Acad Sci U S A, 103, pp.2310~2315 (2006)
- Li YP, "Highly efficient full-length hepatitis C virus genotype 1(strain TN) infectious culture system", Proc Natl Acad Sci U S A, 109, pp.19757~19762 (2012)
- Yamane D, "Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation", Nat Med, 20, pp.927~935 (2014)
- Kim S, "Development of hepatitis C virus genotype 3a cell culture system", Hepatology, 60, pp.1838~1850 (2014)
- Heim MH, "25 Years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end", Nat Rev Immunol, 13, pp.535~542 (2013)
- McHutchison JG, "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group", N Engl J Med, 339, pp.1485~1492 (1998)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Lin R, "Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates: results of the first multicentre Australian trial. Australia Hepatitis C Study Group", J Hepatol, 23, pp.487~496 (1995)
- Poynard T, "A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis: Multicenter Study Group", N Engl J Med, 332, pp.1457~1462 (1995)
- Poordad F, "Boceprevir for untreated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1195~1206 (2011)
- Jacobson IM, "Telaprevir for previously untreated chronic hepatitis C virus infection", N Engl J Med, 364, pp.2405~2416 (2011)
- Lontok E, "Hepatitis C virus drug resistance-associated substitutions: state of the art summary", Hepatology, 62, pp.1623~1632 (2015)
- Shimakami T, "Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus", Gastroenterology, 140, pp.667~675 (2011)
- Appel N, "Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly", PLoS Pathog, 4, pp.e1000035~ (2008)
- Tellinghuisen TL, "Regulation of hepatitis C virion production via phosphorylation of the NS5A protein", PLoS Pathog, 4, pp.e1000032~ (2008)
- Masaki T, "Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles", J Virol, 82, pp.7964~7976 (2008)
- Kim S, "Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III", J Virol, 85, pp.6645~6656 (2011)
- Gao M, "Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect", Nature, 465, pp.96~100 (2010)
- Karino Y, "Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir", J Hepatol, 58, pp.646~654 (2013)
- McGivern DR, "Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors", Gastroenterology, 147(e7), pp.453~462 (2014)
- Tellinghuisen TL, "Structure of the zincbinding domain of an essential component of the hepatitis C virus replicase", Nature, 435, pp.374~379 (2005)